PortfoliosLab logoPortfoliosLab logo
APLS vs. ULTA
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

APLS vs. ULTA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Apellis Pharmaceuticals, Inc. (APLS) and Ulta Beauty, Inc. (ULTA). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

APLS vs. ULTA - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
APLS
Apellis Pharmaceuticals, Inc.
60.15%-21.28%-46.69%15.76%9.37%-17.34%86.81%132.15%-39.22%54.67%
ULTA
Ulta Beauty, Inc.
-13.60%39.11%-11.24%4.46%13.76%43.59%13.44%3.39%9.47%12.28%

Fundamentals

EPS

APLS:

$0.27

ULTA:

$25.63

PE Ratio

APLS:

150.97

ULTA:

20.40

PS Ratio

APLS:

4.90

ULTA:

1.90

Total Revenue (TTM)

APLS:

$689.38M

ULTA:

$12.39B

Gross Profit (TTM)

APLS:

$587.15M

ULTA:

$4.85B

EBITDA (TTM)

APLS:

$55.43M

ULTA:

$1.76B

Returns By Period

In the year-to-date period, APLS achieves a 60.15% return, which is significantly higher than ULTA's -13.60% return.


APLS

1D
135.40%
1M
91.94%
YTD
60.15%
6M
77.77%
1Y
83.95%
3Y*
-15.19%
5Y*
-1.46%
10Y*

ULTA

1D
2.47%
1M
-23.67%
YTD
-13.60%
6M
-4.40%
1Y
42.61%
3Y*
-1.42%
5Y*
10.76%
10Y*
10.41%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

APLS vs. ULTA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

APLS
APLS Risk / Return Rank: 7676
Overall Rank
APLS Sharpe Ratio Rank: 6262
Sharpe Ratio Rank
APLS Sortino Ratio Rank: 9090
Sortino Ratio Rank
APLS Omega Ratio Rank: 9090
Omega Ratio Rank
APLS Calmar Ratio Rank: 7272
Calmar Ratio Rank
APLS Martin Ratio Rank: 6767
Martin Ratio Rank

ULTA
ULTA Risk / Return Rank: 7777
Overall Rank
ULTA Sharpe Ratio Rank: 7979
Sharpe Ratio Rank
ULTA Sortino Ratio Rank: 7575
Sortino Ratio Rank
ULTA Omega Ratio Rank: 7676
Omega Ratio Rank
ULTA Calmar Ratio Rank: 7474
Calmar Ratio Rank
ULTA Martin Ratio Rank: 8282
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

APLS vs. ULTA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Apellis Pharmaceuticals, Inc. (APLS) and Ulta Beauty, Inc. (ULTA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


APLSULTADifference

Sharpe ratio

Return per unit of total volatility

0.56

1.16

-0.59

Sortino ratio

Return per unit of downside risk

2.83

1.80

+1.03

Omega ratio

Gain probability vs. loss probability

1.40

1.25

+0.15

Calmar ratio

Return relative to maximum drawdown

1.51

1.63

-0.12

Martin ratio

Return relative to average drawdown

2.92

6.25

-3.33

APLS vs. ULTA - Sharpe Ratio Comparison

The current APLS Sharpe Ratio is 0.56, which is lower than the ULTA Sharpe Ratio of 1.16. The chart below compares the historical Sharpe Ratios of APLS and ULTA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


APLSULTADifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.56

1.16

-0.59

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.02

0.32

-0.33

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.27

Sharpe Ratio (All Time)

Calculated using the full available price history

0.16

0.37

-0.21

Correlation

The correlation between APLS and ULTA is 0.19, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

APLS vs. ULTA - Dividend Comparison

Neither APLS nor ULTA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

APLS vs. ULTA - Drawdown Comparison

The maximum APLS drawdown since its inception was -82.47%, smaller than the maximum ULTA drawdown of -87.89%. Use the drawdown chart below to compare losses from any high point for APLS and ULTA.


Loading graphics...

Drawdown Indicators


APLSULTADifference

Max Drawdown

Largest peak-to-trough decline

-82.47%

-87.89%

+5.42%

Max Drawdown (1Y)

Largest decline over 1 year

-43.53%

-27.83%

-15.70%

Max Drawdown (5Y)

Largest decline over 5 years

-82.47%

-44.56%

-37.91%

Max Drawdown (10Y)

Largest decline over 10 years

-64.92%

Current Drawdown

Current decline from peak

-56.89%

-26.05%

-30.84%

Average Drawdown

Average peak-to-trough decline

-36.84%

-20.74%

-16.10%

Ulcer Index

Depth and duration of drawdowns from previous peaks

22.49%

7.26%

+15.23%

Volatility

APLS vs. ULTA - Volatility Comparison

Apellis Pharmaceuticals, Inc. (APLS) has a higher volatility of 87.24% compared to Ulta Beauty, Inc. (ULTA) at 17.00%. This indicates that APLS's price experiences larger fluctuations and is considered to be riskier than ULTA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


APLSULTADifference

Volatility (1M)

Calculated over the trailing 1-month period

87.24%

17.00%

+70.24%

Volatility (6M)

Calculated over the trailing 6-month period

100.75%

26.68%

+74.07%

Volatility (1Y)

Calculated over the trailing 1-year period

149.78%

37.09%

+112.69%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

91.24%

34.22%

+57.02%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

84.22%

38.29%

+45.93%

Financials

APLS vs. ULTA - Financials Comparison

This section allows you to compare key financial metrics between Apellis Pharmaceuticals, Inc. and Ulta Beauty, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.001.00B2.00B3.00B4.00BAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026
-114.49M
3.90B
(APLS) Total Revenue
(ULTA) Total Revenue
Values in USD except per share items